COVID-19 Vaccine FDA Presentation 
Bill of Health
APRIL 7, 2023
By Aparajita Lath Two articles published last month in the BMJ analyze the public investment and financing of mRNA COVID-19 vaccines, highlighting the extensive government funding that has supported the development of mRNA technology from 1985 to 2022. government substantially de-risking the vaccine development process.
SQA
JUNE 10, 2021
ANVISA released on 05 March the report Regulation in Numbers , presenting the 2020 actions aiming to improve the regulatory quality of the Agency. Backgrounder – Government of Canada Investments in Biomanufacturing, Development of COVID-19 Vaccines and Therapeutics, and Research, 18 May 2021. National Research Council.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Health Populi
JUNE 24, 2021
On the pharma supply side, mRNA vaccines will dominate the market, proving more effective than others at stemming a further outbreak. With growing global supply and competition, we can expect prices for COVID-19 vaccines to fall, anticipating additional volumes from Sinopharm, Moderna, Sinovac, Gamaleya Institute, among others.
SQA
MAY 24, 2021
Even with more of the world receiving their Covid-19 vaccinations, there are some countries lagging behind or dealing with a different strain. These continued hurdles are met with passion to succeed from SQA clients producing more vaccines to increase supply, and other options to fight Covid-19. Challenges.
HIT Consultant
AUGUST 18, 2021
The world has been in urgent need of COVID-19 vaccines, treatments, and diagnostic tools. The rapid adoption of decentralized and hybrid clinical study design spurred by the pandemic will present new regulatory challenges for the foreseeable future. Ronan Brown, SVP and Head of Integrated Global Compliance, IQVIA.
SQA
MARCH 25, 2021
The concepts presented in PDA Technical Report No. United States Food and Drug Administration (FDA) – Regulations and Guidances for Biologics and the Bioresearch Monitoring Program (BIMO). Coronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing SARS-CoV-2 Virus Variants, 22 February 2021.
Bill of Health
JANUARY 7, 2022
The American booster push was controversial, because the scientific evidence on the need for and effectiveness of boosters was limited, and the White House exerted an unprecedented level of pressure on the FDA and CDC’s ‘independent’ scientific review processes. Ultimately, both the FDA and CDC gave their blessing to boosters.
Expert insights. Personalized for you.
147 
Let's personalize your content